Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511317 | 0.92 | DRD2 (0.64) | DRD2PKMMAPK1TSHRTP53 | |
| SCHEMBL14569973 | 0.88 | TSHR (0.62) | DRD2PKMMAPK1TSHRTP53 | |
| SCHEMBL14569823 | 0.86 | DRD2 (0.62) | DRD2PKMMAPK1TSHRTP53 | |
| SCHEMBL1981044 | 0.83 | PKM (0.62) | DRD2PKMMAPK1TSHRTP53 | |
| SCHEMBL13529999 | 0.82 | DRD2 (0.51) | DRD2PKMMAPK1TSHRTP53 | |
| Hydrochloric Acid SCHEMBL5070229 | 0.82 | PKM (0.61) | DRD2PKMMAPK1TSHRTP53 | |
| SCHEMBL22831363 | 0.82 | ALDH1A1 (0.59) | TSHRALDH1A1 | |
| SCHEMBL14569696 | 0.81 | TSHR (0.66) | PKMTSHRALDH1A1 | |
| SCHEMBL14569695 | 0.81 | PKM (0.56) | DRD2PKMMAPK1TSHRTP53 | |
| Hydrochloric Acid SCHEMBL21225052 | 0.81 | PKM (0.59) | DRD2PKMMAPK1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | DRD2 3285/4885PKM 1845/4885MAPK1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.